Researchers at the University of Virginia have discovered a new mechanism driving drug resistance in pancreatic ductal ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...

Pancreatic ductal adenocarcinoma (PDAC) is recognized as one of the most lethal cancers, with an estimated five-year survival ...

But the event was significant beyond scientific camaraderie. The Pancreatic Cancer Early Detection Consortium — often called ...

The gut microbiome's impact on pancreatic cancer highlights potential for early screening and fecal microbiota ...

University of Virginia researchers advance understanding of chemoresistance in pancreatic cancer, offering hope for new ...

DelveInsight’s Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

A new study by researchers at the Karolinska Institute and the University of Hamburg suggests liquid biopsy may revolutionize ...

In recent research published in eGastroenterology, Dr. J-Matthias Löhr and colleagues provide an in-depth review of ...

The poster presentation, entitled "CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ...

The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...